ALNY

$0.00

(

0.00%

)
Quote details

stock

Alnylam Pharmaceuticals Inc

NASDAQ | ALNY

471.32

USD

$0.00

(

0.00%

)

At Close (As of Dec 4, 2025)

$62.53B

Market Cap

1690.32

P/E Ratio

0.28

EPS

$495.55

52 Week High

$205.87

52 Week Low

HEALTHCARE

Sector

ALNY Chart

Recent Chart
Price Action

ALNY Technicals

Tags:

ALNY Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1.9B
Total Revenue $2.2B
Cost Of Revenue $323M
Costof Goods And Services Sold $323M
Operating Income -$177M
Selling General And Administrative $976M
Research And Development $1.1B
Operating Expenses $2.1B
Investment Income Net -
Net Interest Income -$20M
Interest Income $122M
Interest Expense $142M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $57M
Income Before Tax -$377M
Income Tax Expense -$99M
Interest And Debt Expense -
Net Income From Continuing Operations -$278M
Comprehensive Income Net Of Tax -
Ebit -$236M
Ebitda -$179M
Net Income -$278M

Revenue & Profitability

Earnings Performance

ALNY Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $4.2B
Total Current Assets $3.3B
Cash And Cash Equivalents At Carrying Value $966M
Cash And Short Term Investments $966M
Inventory $79M
Current Net Receivables $405M
Total Non Current Assets $945M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $1.7B
Other Current Assets $117M
Other Non Current Assets -
Total Liabilities $4.2B
Total Current Liabilities $1.2B
Current Accounts Payable $88M
Deferred Revenue -
Current Debt -
Short Term Debt $155M
Total Non Current Liabilities $3B
Capital Lease Obligations $271M
Long Term Debt $1B
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $2.7B
Other Current Liabilities $887M
Other Non Current Liabilities $1.7B
Total Shareholder Equity $67M
Treasury Stock -
Retained Earnings -$7.3B
Common Stock $1.3M
Common Stock Shares Outstanding $128M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$8.3M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $57M
Capital Expenditures $34M
Change In Receivables -
Change In Inventory $14M
Profit Loss -
Cashflow From Investment -$117M
Cashflow From Financing $294M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$278M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1.9B
Total Revenue $2.2B
Cost Of Revenue $323M
Costof Goods And Services Sold $323M
Operating Income -$177M
Selling General And Administrative $976M
Research And Development $1.1B
Operating Expenses $2.1B
Investment Income Net -
Net Interest Income -$20M
Interest Income $122M
Interest Expense $142M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $57M
Income Before Tax -$377M
Income Tax Expense -$99M
Interest And Debt Expense -
Net Income From Continuing Operations -$278M
Comprehensive Income Net Of Tax -
Ebit -$236M
Ebitda -$179M
Net Income -$278M

ALNY News

ALNY Profile

Alnylam Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Alnylam Pharmaceuticals, Inc. is a pioneering biopharmaceutical company headquartered in Cambridge, Massachusetts, specializing in the development and commercialization of transformative RNA interference (RNAi) therapeutics aimed at addressing genetic diseases. The company boasts a robust pipeline of innovative RNAi-based therapies and has made significant strides in the market, including the successful launch of its first commercial product. With a steadfast commitment to scientific excellence and the advancement of medicine, Alnylam is positioned as a leader in the biopharmaceutical sector, striving to redefine treatment paradigms for both rare and prevalent diseases.

LPTX
+368.57%
$2.05
IXHL
+12.68%
$0.44
PAVS
-6.76%
$0.03
VHAI
-33.33%
$0.00
KALA
+22.16%
$1.13
NVDA
+1.46%
$182.21
ASST
-6.00%
$0.98
PMCB
+82.25%
$1.43
PLUG
-1.34%
$2.20
IPG
-1.95%
$24.57
QCLS
+49.14%
$6.96
KITT
-23.70%
$1.19
ONDS
+1.84%
$9.08
AXDX
-61.36%
$0.03
INTC
-6.09%
$41.09
TNFA
+38.16%
$4.67
RR
+9.95%
$4.64
TSLA
+0.27%
$447.98
ADAP
-15.14%
$0.05
RGTI
+12.74%
$29.36
BBD
-2.35%
$3.58
ACHR
+5.32%
$8.79
BYND
+3.60%
$1.29
SOND
-23.45%
$0.12
BITF
-0.96%
$3.08
SOFI
+0.17%
$29.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
QBTS
+13.71%
$28.52
ADD
-25.47%
$0.05
NIO
+3.42%
$4.95
VALE
+2.20%
$13.59
AAL
-0.90%
$14.42
SRM
+53.27%
$10.30
NFLX
-0.92%
$102.99
IONZ
-24.03%
$3.16
IRBT
-12.53%
$2.96
SMR
+15.55%
$23.27
DNN
+5.04%
$2.83
AMZN
-1.54%
$228.79
BMNU
+9.42%
$8.84
WLGS
-5.57%
$0.04
AMD
+1.09%
$217.60
F
+0.15%
$13.11
MTSR
-0.35%
$70.50
BMNR
+4.05%
$35.02
PLTD
+0.14%
$6.74
PMI
+50.24%
$3.03
WBD
-1.41%
$24.22
IONQ
+12.79%
$54.87
INHD
+6.47%
$0.14
ASBP
-10.81%
$0.08
PFSA
+2.52%
$0.19
META
+3.84%
$664.22
BTBT
0.00%
$2.33
IREN
+1.79%
$44.75
PLRZ
+95.34%
$13.85
AFMD
-34.94%
$0.18
CMG
-0.61%
$33.93
RIVN
-0.57%
$17.42
PLTR
+0.56%
$177.07
BAC
+0.16%
$54.18
CLSK
+0.05%
$14.49
SNAP
+0.06%
$7.66
CIFR
+5.92%
$19.73
PSTG
-27.31%
$68.85
AAPL
-1.88%
$278.78
WULF
+1.17%
$14.59
KVUE
+0.08%
$16.98
MSPR
+13.79%
$0.31
CRWV
+8.36%
$85.99
TWOH
0.00%
$0.00
GOOGL
-0.84%
$316.94
BURU
+2.23%
$0.23
PFE
+0.23%
$25.63
SOUN
+6.23%
$12.51
MARA
-0.52%
$12.40
GRAB
+1.23%
$5.33
ABLV
+47.15%
$1.06
EOSE
+16.75%
$15.82
GRYP
-10.38%
$1.38
QUBT
+7.82%
$13.01
VIVK
+12.34%
$0.10
MODV
-25.22%
$0.43
ITUB
+1.64%
$8.05
CAN
-1.56%
$0.95
TSLG
+8.25%
$9.97
ASTS
+18.47%
$72.79
T
+0.17%
$25.36
RKLB
+8.16%
$48.37
MU
-2.86%
$227.44
RIG
+0.11%
$4.45
ORCL
+2.92%
$213.80
KDLY
+11.70%
$0.54
KR
-3.89%
$63.61
CHR
-1.24%
$0.03
USAR
+20.08%
$16.83
CGC
+3.87%
$1.20
HIMS
+7.93%
$40.01
YGMZ
-17.32%
$0.06
LPTX
+368.57%
$2.05
IXHL
+12.68%
$0.44
PAVS
-6.76%
$0.03
VHAI
-33.33%
$0.00
KALA
+22.16%
$1.13
NVDA
+1.46%
$182.21
ASST
-6.00%
$0.98
PMCB
+82.25%
$1.43
PLUG
-1.34%
$2.20
IPG
-1.95%
$24.57
QCLS
+49.14%
$6.96
KITT
-23.70%
$1.19
ONDS
+1.84%
$9.08
AXDX
-61.36%
$0.03
INTC
-6.09%
$41.09
TNFA
+38.16%
$4.67
RR
+9.95%
$4.64
TSLA
+0.27%
$447.98
ADAP
-15.14%
$0.05
RGTI
+12.74%
$29.36
BBD
-2.35%
$3.58
ACHR
+5.32%
$8.79
BYND
+3.60%
$1.29
SOND
-23.45%
$0.12
BITF
-0.96%
$3.08
SOFI
+0.17%
$29.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
QBTS
+13.71%
$28.52
ADD
-25.47%
$0.05
NIO
+3.42%
$4.95
VALE
+2.20%
$13.59
AAL
-0.90%
$14.42
SRM
+53.27%
$10.30
NFLX
-0.92%
$102.99
IONZ
-24.03%
$3.16
IRBT
-12.53%
$2.96
SMR
+15.55%
$23.27
DNN
+5.04%
$2.83
AMZN
-1.54%
$228.79
BMNU
+9.42%
$8.84
WLGS
-5.57%
$0.04
AMD
+1.09%
$217.60
F
+0.15%
$13.11
MTSR
-0.35%
$70.50
BMNR
+4.05%
$35.02
PLTD
+0.14%
$6.74
PMI
+50.24%
$3.03
WBD
-1.41%
$24.22
IONQ
+12.79%
$54.87
INHD
+6.47%
$0.14
ASBP
-10.81%
$0.08
PFSA
+2.52%
$0.19
META
+3.84%
$664.22
BTBT
0.00%
$2.33
IREN
+1.79%
$44.75
PLRZ
+95.34%
$13.85
AFMD
-34.94%
$0.18
CMG
-0.61%
$33.93
RIVN
-0.57%
$17.42
PLTR
+0.56%
$177.07
BAC
+0.16%
$54.18
CLSK
+0.05%
$14.49
SNAP
+0.06%
$7.66
CIFR
+5.92%
$19.73
PSTG
-27.31%
$68.85
AAPL
-1.88%
$278.78
WULF
+1.17%
$14.59
KVUE
+0.08%
$16.98
MSPR
+13.79%
$0.31
CRWV
+8.36%
$85.99
TWOH
0.00%
$0.00
GOOGL
-0.84%
$316.94
BURU
+2.23%
$0.23
PFE
+0.23%
$25.63
SOUN
+6.23%
$12.51
MARA
-0.52%
$12.40
GRAB
+1.23%
$5.33
ABLV
+47.15%
$1.06
EOSE
+16.75%
$15.82
GRYP
-10.38%
$1.38
QUBT
+7.82%
$13.01
VIVK
+12.34%
$0.10
MODV
-25.22%
$0.43
ITUB
+1.64%
$8.05
CAN
-1.56%
$0.95
TSLG
+8.25%
$9.97
ASTS
+18.47%
$72.79
T
+0.17%
$25.36
RKLB
+8.16%
$48.37
MU
-2.86%
$227.44
RIG
+0.11%
$4.45
ORCL
+2.92%
$213.80
KDLY
+11.70%
$0.54
KR
-3.89%
$63.61
CHR
-1.24%
$0.03
USAR
+20.08%
$16.83
CGC
+3.87%
$1.20
HIMS
+7.93%
$40.01
YGMZ
-17.32%
$0.06

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.